A review of potential candidate genes polymorphism responsible for schiz-ophrenia risk

Indu Priya¹ , Sakshi Sharma² , Isar Sharma³ , Ritu Mahajan⁴ , Nisha Kapoor⁵

Section:Review Paper, Product Type: Isroset-Journal
Vol.5 , Issue.6 , pp.186-195, Dec-2018

CrossRef-DOI:   https://doi.org/10.26438/ijsrbs/v5i6.186195

Online published on Jan 01, 2018

Copyright © Indu Priya, Sakshi Sharma, Isar Sharma, Ritu Mahajan , Nisha Kapoor . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

715 Views    203 Downloads    114 Downloads

Abstract :
Schizophrenia (SCZ) is a strong heritable disorder that involves multiple gene combination, each conferring a little increase in the burden to the disease. Due to the complexity of disease, it is difficult to find susceptible genes and promising biomarker. The true etiology of SCZ is still not fully understood, however, recent studies on SCZ molecular genetics, with a focus on candidate genes approach affirms and predicate association with SCZ. Some investigators have reported the involvement of environment factors in the formation and progression of the Schizophrenia. Literature has been surveyed that reports association between genetic variation and SCZ also between genetic polymorphisms and clinical outcomes. The present study focuses on human populations to review SNPs of various genes which show best association with the disease. We have identified 60 published case control studies that have studied association of various SNPs in different population.

Key-Words / Index Term :
Association studies, Schizophrenia, SNPs, Genes, Inheritance

References :
[1]. World Health Organization, “The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostics guidelines”, Geneva: World Health Organisation, 1992.
[2]. American Psychiatric Association, Diagnostic and statistical manual of mental disorders (4 ed., text rev.), 2000.
[3]. S.H. Fatemi, T.D. Folsom, “The neurodevelopmental hypothesis of schizophrenia, revisited”, Schizophrenia Bulletin, Vol. 35, Issue, 3, pp. 528-548, 2009.
[4]. P.A. Holmans, B. Riley, A.E. Pulver, M.J. Owen, D.B. Wildenauer, P.V. Gejman, … D.F. Levinson, “Genome wide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms”, Molecular Psychiatry, Vol. 14, pp. 786-795, 2009.
[5]. L. Michelon, H. Vallada, “Genetica do transtorno bipolar”, Revista Brasileira de Psiquiatria, Vol. 26, pp. 12-16, 2004.
[6]. M. Emily, T. Mailund, J. Hein, L. Schauser, M.H. Schierup, “Using biological networks to search for interacting loci in genome-wide association studies”, European Journal of Human Genetics, Vol. 17, pp. 1231-1240, 2006.
[7]. B.P.F. Rutten, J. Mill, “Epigenetic mediation of environmental influences in major psychotic disorders” Schizophrenia Bulletin, Vol. 35, pp. 1045-1056, 2009.
[8]. Y. Ayhana, R. McFarland, M.V. Plentikov, “Animal models of gene -environment interaction in schizophrenia: A dimensional perspective”, Progress in Neurobiology, Vol. 136, pp. 1–27, 2015.
[9]. H.Y. Meltzer, “Treatment-Resistant Schizophrenia - The Role of Clozapine” Current Medical Research and Opinion, Vol. 14, pp. 1-20, 1997.
[10]. H. Elkis, P.F. Buckeley, “Treatment Resistant Schizophrenia”, Psychiatric Clinics of North America, Vol. 39, pp. 239-265, 2016.
[11]. P.J. Harrison, D.R Weinberger, “Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence”, Molecular Psychiatry, Vol. 10, pp. 40-68, 2005.
[12]. B. Misiak, F. Stramecki, L. Gawęda, K. Prochwicz, M.M. Sąsiadek, A.A. Moustafa, D. Frydecka, “Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review”, Molecular Neurobiology, Vol. 55, pp. 5075-5100, 2017.
[13]. P.F. Sullivan, K.S. Kendler, Neale, “Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies”, Archives of General Psychiatry, Vol. 60, pp. 1187–1192, 2003.
[14]. S.S. Kety, “Schizophrenic illness in the families of schizophrenic adoptees: findings from the Danish national sample”, Schizophrenia Bulletin, Vol. 14, pp. 217-222, 1998.
[15]. J.A. Veltman, H.G. Brunner, “De novo mutations in human genetic disease”, Nature Reviews Genetics, Vol. 13, pp. 565-575, 2012.
[16]. A. Kong, M.L. Frigge, G. Masson, S. Besenbacher, P. Sulem, G. Magnusson, K. Stefansson, “Rate of de novo mutations and the importance of father`s age to disease risk”, Nature, Vol. 488, pp. 471-475, 2012.
[17]. J.J. McGrath, L. Petersen, E. Agerbo, O. Mors, P. Mortensen, C. Pedersen, “A comprehensive assessment of parental age and psychiatric disorders”, JAMA Psychiatry Vol. 71, pp. 301-309, 2014.
[18]. S.M. Purcell, N.R. Wray, J.L. Stone, P.M. Visscher, M.C. O’Donovan, P.F. Sullivan, P. Sklar, “Common polygenic variation contributes to risk of schizophrenia and bipolar disorder”, Nature, Vol. 460, pp. 748-752, 2009.
[19]. J. Shi, D.F. Levinson, J. Duan, A.R. Sanders, Y. Zheng, I. Pe’er, F. Dudbridge, P.A. Holmans, A.S. Whittemore, B.J. Mowry, A. Olincy, F. Amin, C.R. Cloninger, J.M. Silverman, N.G. Buccola, W.F. Byerley, D.W. Black, R.R. Crowe, J.R. Oksenberg, D.B. Mirel, K.S. Kendler, R. Freedman, P.V. Gejman, “Common variants on chromosome 6p22.1 are associated with schizophrenia”, Nature, Vol. 60, pp. 753-757, 2009.
[20]. H. Stefansson, R.A. Ophoff, S. Steinberg, O.A. Andreassen, S. Cichon, D. Rujescu, … D.A. Collier, “Common variants conferring risk of schizophrenia”, Nature, Vol. 460, pp. 744-747, 2009.
[21]. International Schizophrenia Consortium, “Rare Chromosomal deletions and duplications increase risk of schizophrenia”, Nature, Vol. 455, pp. 237-241, 2008.
[22]. D. Malhotra, S. McCarthy, J.J. Michaelson, V. Vacic, E.B. Katherine, S. Yoon, S. Cichon, A. Corvin, S. Gary, S.G. Elliot, M. Gill, M. Karayiorgou, J.R. Kelsoe, O. Krastoshevsky, V. Krause, E. Leibenluft, D.L. Levy, V. Makarov, A. Bhandari, A.K. Malhotra, F.J. McMohan, M.M. Nathan, J.B. Potash, M. Rietschell, T.G. Schilze, J. Sebat, “High frequencies of de novo CNVs in bipolar disorder and schizophrenia”, Neuron, Vol. 72, pp. 951-963, 2011.
[23]. B. Xu, J.L. Roos, J.L., S. Levy, E.J.V. Rensburg, J.A. Gogos, M. Karayiorgou, “Strong association of de novo copy number mutations with sporadic schizophrenia”, Nature Genetics, Vol.40, pp. 880-885, 2008.
[24]. A.A. Mitchell, A. Chakravarti, D.J. Cutler, D.J, “On the probability that a novel variant is a disease-causing mutation”, Genome Research, Vol. 15, pp. 960–996, 2005.
[25]. Schizophrenia Working Group of the Psychiatric Genomics Consortium, S. Ripke, B.M. Neale, A. Corvin, J.T.R. Walters, … M.C. O’Donovan, “Biological Insights From 108 Schizophrenia-Associated Genetic Loci”, Nature, Vol. 511, pp. 421–427, 2014.
[26]. S. Ripke, C. O’Dushlaine, K. Chambers, J.L. Moran, A.K. Kahler, S. Akterin, … P.F. Sullivan, “Genome-wide association analysis identifies 13 new risk loci for schizophrenia”, Nature Genetics, Vol. 45, pp. 1150-115, 2013.
[27]. T.L. Huang, T.C. Lee, “Associations between Brain-derived Neurotrophic Factor G196A Gene Polymorphism and Clinical Phenotypes in Schizophrenia Patients”, Chang Gung Medical Journal, Vol. 30, pp. 408-413, 2007.
[28]. W. Li, N. Zhou, Q. Yu, X. Li, Y. Yu, S. Sun, C. Kou, D.C. Chen, M.H. Xiu, T.R. Kosten, X.Y. Zhang, “Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a chinese population”, American Journal of Medical Genetics, 2013.
[29]. X.Y. Zhang, D.C. Chen, Y.L. Tan, Y.L. Tan, S.P. Tan, X. Luo, L. Zuo, J.C. Soares, “BDNF polymorphisms are associated with schizophrenia onset and positive symptoms” Schizophrenia Research, Vol. 170, pp. 41–47, 2016.
[30]. H. Xia, G. Zhang, X. Du, Y. Zhang, G. Yin, J. Dai, M.X. He, J.C. Soares, X. Li, X.Y. Zhang, “Suicide Attempt, Clinical Correlates, and BDNF Val66Met Polymorphism in Chronic Patients With Schizophrenia”, Neuropsychology, 2017.
[31]. P.J. Harrison, D.R. Weinberger, “Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence”, Molecular Psychiatry, Vol. 10, pp. 40-68, 2005.
[32]. K. Imai, S. Harada, Y. Kawanishi, H. Tachikawa, T. Okubo, T. Suzuki, “The (CTG)n polymorphism in the NOTCH4 gene is not associated with schizophrenia in Japanese individuals”, BMC Psychiatry, Vol. 1, pp. 1, 2001.
[33]. B. Zhang, Q.R. Fan, W.H. Li, N. Lu, D.K. Fu, Y.J. Kang, N. Wang, T. Li, X.P. Wen, X.D. Li, “Association of the NOTCH4 Gene Polymorphism rs204993 with Schizophrenia in the Chinese Han Population”, BioMedical Research International, Vol. 408096, 2015.
[34]. H.J. Park, J.K. Park, S.K. Kim, A.R. Cho, J.W. Kim, S.V. Yim, J.H. Chung, “Association of Polymorphism in the Promoter of the Melatonin Receptor 1A Gene with Schizophrenia and with Insomnia Symptoms in Schizophrenia Patients”, Journal of Molecular Neuroscience, Vol. 45, pp. 304, 2011.
[35]. M.E. Benros, P.B. Mortensen, W.W. Eaton, “Autoimmune diseases and infections as risk factors for schizophrenia”, Annals of the New York Academics Science, Vol. 1262, pp.56–66, 2012.
[36]. W.W. Eaton, M. Byrne, H. Ewald, O. Mors, C.Y. Chen, E. Agerbo, P.B. Mortensen, “Association of schizophrenia and autoimmune diseases: linkage of Danish national registers”, American Journal of Psychiatry, Vol. 163, Issue, 3, pp. 521–528, 2006.
[37]. P. Kapelski, M. Skibinska, M. Maciukiewicz, M. Wilkosc, D. Frydecka, A. Groszewska, B. Narozna, M. Dmitrzak-Weglarza, P. Czerskia, A. Pawlaka, A. Rajewska-Rager, A. Leszczynka-Rodziewicz, A. Slopienh, D. Zaremba, J. Twarowska-Hauser, “Association study of functional polymorphisms in interleukins and interleukin receptors genes: IL1A, IL1B, IL1RN, IL6, IL6R, IL10, IL10RA and TGFB1 in schizophrenia in Polish population”, Schizophrenia Research, Vol. 16, pp. 1-9, 2015.
[38]. M. Paul-Samojedny, M. Kowalczyk, R. Suchanek, A. Owczarek, A. Fila-Danilow, A. Szczygiel, J. Kowalski, “Functional Polymorphism in the Interleukin-6 and Interleukin-10 Genes in Patients with Paranoid Schizophrenia —A Case-Control Study”, Journal of Molecular Neuroscience, Vol. 42, pp. 112-119, 2010.
[39]. M. Paul-Samojedny, A. Owczarek, M. Kowalczyk, R. Suchanek, M. Palacz, K. Kucia, A. Fila-Daniłow, P. Borkowska, J. Kowalski, “Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFα) gene polymorphisms with paranoid schizophrenia in a Polish population”, Journal Neuropsychiatry and Clinical Neuroscience, Vol. 25, pp.72-82, 2013.
[40]. R. Zakharyan, A. Khoyetsyan, A. Arakelyan, A. Boyajyan, A. Gevorgyan, A. Stahelova, F. Mrazek, M. Petrek, “Association of C1QB gene polymorphism with schizophrenia in Armenian population”, BMC Medical Genetics, Vol. 12, pp. 126, 2011.
[41]. R.D. Strous, N.G. Bark, S.S. Parsia, J. Volavka, H.M. Lachmanc, “Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behaviour”, Psychiatry Research, Vol. 69, pp. 71-77, 1997.
[42]. S.A. Ivanova, M.L. Filipenko, N.M. Vyalova, E.N. Voronina, V.I. Pozhidaev, D.Z. Osmanova, M.V. Ivanov, O.Y. Fedorenko, A.V. Semke, N.A. Bokhan, N.A. (2015). CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Bulletin of Experimental Biology and Medicine, Vol. 160, pp. 5, 2015.
[43]. J. Scharfetter, H.R. Chaudhry, K. Hornik, K. Fuchs, W. Sieghartd, S. Kaspera, H.N. Aschauera, “Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients”, European Neuropsychopharmacology, Vol. 10, pp. 17-20, 1990.
[44]. C.H. Chen, M.L. Lua, P.H. Kuoc, P.Y. Chene, C.C. Chiu, C.F. Kaoc, M.C. Huang, “Gender differences in the effects of peroxisome proliferator activated receptor γ2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder”, Progress in Neuropsychopharmacology and Biological Psychiatry, Vol. 35, Issue, 1, pp. 239-245, 2011.
[45]. L. Su, T. Shen, G. Huang, J. Long, J. Fan, W. Ling, J. Jiang, “Genetic association of GWAS-supported MAD1L1 gene polymorphism rs12666575 with schizophrenia susceptibility in a Chinese population”, Neuroscience Letter, Vol. 610, pp. 98-103, 2016.
[46]. D. Frydecka, B. Misiak, J.A. Beszlej, L. Karabon, E. Pawlak-Adamska, A. Tomkiewicz, A. Partyka, A. Jonkisz, A. Kiejna, “Genetic variants in transforming growth factor-β gene (TGFB1) affect susceptibility to schizophrenia”, Molecular Biology Reports, Vol. 40, Issue, 10, pp. 5607–5614, 2013.
[47]. C.M. Lewis, D.F. Levinson, L.H. Wise, L.E. DeLisi, R.E. Straub, I. Hovatta, … T. Helgason, “Genome-scan meta analysis of schizophrenia and bipolar disorder, partII: Schizophrenia”, American Journal Human Genetics, Vol. 73, pp. 34 –48, 2009.
[48]. M. Holtze, P. Saetre, G. Engberg, L. Schwieler, T. Werge, O.A. Andreassen, H. Hall, L. Terenius, I. Agartz, E.G. Jonsson, M. Schalling, S. Erhardt, “Kynurenine 3-monooxygenase polymorphisms:relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls”, Journal of Psychiatry Neuroscience, Vol. 37, pp. 1, 2011.
[49]. H. Hori, O. Ohmori, T. Shinkai, H. Kojima, C. Okano, T. Suzuki, J. Nakamura, “Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia”, Neuropsychopharmacology, Vol. 23, pp. 2, 2000.
[50]. K.R. Saradalekshmi, N.V. Neetha, S. Sathyan, I.V. Nair, C.M. Nair, M. Banerjee, “DNA Methyl Transferase (DNMT) Gene Polymorphisms Could Be a Primary Event in Epigenetic Susceptibility to Schizophrenia.”, Plos One, 2014.
[51]. S.P Sujitha, A. Nair, M. Banerjee, S. Lakshmanan, S. Harshavaradhan, S. Gunasekaran, A. Gopinathan, “5-Hydroxytryptamine (serotonin) 2A receptor gene polymorphism is associated with schizophrenia”, Indian Journal Medical Research, Vol. 140, pp. 736-743, 2014.
[52]. M. Naz, M. Riaz, M. Saleem, “Potential role of Neurkgulin 1 and TNFalpha (−308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan”, Molecular Biology Reports, Vol. 38, pp. 4709–4714, 2011.
[53]. S. Kadasah, M. Arfin, S. Rizvi, M. Al-Asmari, A. Al-Asmari, “Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia”, Neuropsychiatric and Disease Treatment, Vol. 13, pp. 1081–1088, 2017.
[54]. J. Long, G. Huang, B. Liang, W. Ling, X. Guo, J. Jiang, L. Su, “The dopamine beta-hydroxylase gene polymorphism rs1611114 is associated with schizophrenia in the Chinese Zhuang but not Chinese Han population”, Molecular Genetics and Genomics, Vol. 291, pp. 1813–1821, 2016.
[55]. M.J. Girgenti, J.J. LoTurco, B.J. Maher, “ZNF804a Regulates Expression of the Schizophrenia-Associated Genes PRSS16, COMT, PDE4B, and DRD2”, PLOS ONE, 2012.
[55]. Y. Bi, X. Huang, W. Niu, S. Chen, X. Wu, Y. Cao, R. Zhang, F. Yang, L. Wang, W. Li, Y. Xu, L. He, T. Yu, G. He, X. Li, X., “No association between SLC6A2, SLC6A3, DRD2 polymorphisms and schizophrenia in the Han Chinese population”, Psychiatry Research, Vol. 53, pp. 398-400, 2017.
[56]. W. Guo, Y.Z. Cai, H. Zhang, Y. Yang, G. Yang, X. Wang, … L. Lv, “Association of ARHGAP18 polymorphisms with schizophrenia in the Chinese-Han population”, PLOS ONE, 2017.
[57]. H.U. Guoqin, C. Yang, J. Zhao, M. ZHU, X. GUO, C. BAO, … Z. YI, “Association of schizophrenia with the rs821633 polymorphism in the DISC1 gene among Han Chinese”, Shanghai Archives of Psychiatry, Vol. 25, pp. 348–355, 2015.
[58]. J.S. Bae, J.Y. Kim, B. Park, H.S. Cheong, J.S. Kim, J.G. Shin, … S. Woo, “Lack of association between DISC1 polymorphisms and risk of schizophrenia in a Korean population”, Psychiatry Research, Vol. 208, pp. 189-191, 2013.
[59]. H. Galehdari, “Association Between the G1001C Polymorphism in the GRIN1 Gene Promoter and Schizophrenia in the Iranian Population”, Journal of Molecular Neuroscience, Vol. 38, pp. 178, 2009.
[60]. P.F. Sullivan, K.S. Kendler, Neale, “Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies”, Archives of General Psychiatry, Vol. 60, pp. 1187–1192, 2003.